The variability in beta‐cell function in placebo‐treated subjects with type 2 diabetes: application of the weight‐HbA1c‐insulin‐glucose (WHIG) model. (17th November 2016)

• Record Type: Journal Article
• Authors: Duong, Janna K.; de Winter, Willem; Choy, Steve; Plock, Nele; Naik, Himanshu; Krauwinkel, Walter; Visser, Sandra A.G.; Verhamme, Katia M.; Sturkenboom, Miriam C.; Stricker, B.H.; Danhof, Meindert
• Is Part Of: British journal of clinical pharmacology. Volume 83:Number 3(2017:Mar.)
• Page Start: 487
• Page End: 497
• Publication Date: 2016-11-17
• Subjects: beta‐cell function -- disease progression -- placebo treatment -- semi‐mechanistic modelling -- type 2 diabetes mellitus; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.13144
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aim: The weight‐glycosylated haemoglobin (HbA1C)‐insulin‐glucose (WHIG) model describes the effects of changes in weight on insulin sensitivity (IS) in newly diagnosed, obese subjects receiving placebo treatment. This model was applied to a wider population of placebo‐treated subjects, to investigate factors influencing the variability in IS and β‐cell function. Methods: The WHIG model was applied to the WHIG dataset (Study 1) and two other placebo datasets (Studies 2 and 3). Studies 2 and 3 consisted of nonobese subjects and subjects with advanced type 2 diabetes mellitus (T2DM). Body weight, fasting serum insulin (FSI), fasting plasma glucose (FPG) and HbA1c were used for nonlinear mixed‐effects modelling (using NONMEM v7.2 software). Sources of interstudy variability (ISV) and potential covariates (age, gender, diabetes duration, ethnicity, compliance) were investigated. Results: An ISV for baseline parameters (body weight and β‐cell function) was required. The baseline β‐cell function was significantly lower in subjects with advanced T2DM (median difference: Study 2: 15.6%, P < 0.001; Study 3: 22.7%, P < 0.001) than in subjects with newly diagnosed T2DM (Study 1). A reduction in the estimated insulin secretory response in subjects with advanced T2DM was observed but diabetes duration was not a significant covariate. Conclusion: The WHIG model can be used to describe the changes in weight, IS and β‐cell function in the diabetic population. IS remained relatively stable between subjects but a large ISV in β‐cell function was observed. There was a trend towards decreasing β‐cell responsiveness with diabetes duration, and further studies, incorporating subjects with a longer history of diabetes, are required.